Veradermics Reports Positive Phase 2 Topline Data for VDPHL01 in Female Pattern Hair Loss, Showing Average Hair Count Gains Above 22 Hairs per cm²

Veradermics and Its Lead Product Candidate VDPHL01

Veradermics, Incorporated is a specialty dermatology company incorporated in Delaware and headquartered at 470 James Street, New Haven, Connecticut. The company is classified as an emerging growth company and has a limited operating history, with no products currently approved for commercial sale. Its business model is centered on the development and eventual commercialization of VDPHL01, an extended-release oral minoxidil formulation designed to treat pattern hair loss in both male and female patients.

VDPHL01 is described in the company's disclosure as a proprietary formulation, distinguishing it from conventional immediate-release oral minoxidil products already available in the market. The company has identified VDPHL01 as its lead product candidate, and its filing states that the success of the organization is expected to depend substantially on the approval and successful commercialization of this compound. The company has acknowledged that it anticipates incurring substantial and increasing losses for the foreseeable future and will require additional financing to achieve its development and commercial objectives.

Structure and Design of Study '207'

Study '207' is described in the disclosure as a multicenter, Phase 2, open-label clinical trial. The study enrolled a total of 49 participants, comprising 21 adult male patients and 28 adult female patients with pattern hair loss. The primary objective of the trial was to obtain proof of concept for the safety and efficacy of twelve months of treatment with VDPHL01 across both patient populations.

For male participants, the study evaluated VDPHL01 at a dose of 8.5 mg administered twice daily. For female participants, the trial assessed two distinct dosing regimens: VDPHL01 4.5 mg once daily and VDPHL01 4.5 mg twice daily. The open-label design means all participants and investigators were aware of the treatment being administered, which is a characteristic common to proof-of-concept Phase 2 studies. The topline data disclosed on July 15, 2026, specifically addresses the results observed among female participants at the six-month measurement point.

Hair Count Outcomes Among Female Participants at Month 6

The company disclosed that among female participants in Study '207,' VDPHL01 achieved statistically noteworthy results on the primary endpoint of non-vellus Target Area Hair Count at Month 6. Participants in the once daily dosing arm achieved an average increase in non-vellus hair count of 22.7 hairs per cm², while those in the twice daily arm achieved an average increase of 23.3 hairs per cm². The company characterized these results as consistent across participants, suggesting a reliable treatment response rather than an outcome driven by a small subset of high responders.

The disclosure further noted that VDPHL01 demonstrated what the company described as a potentially differentiated clinical profile, defined by rapid onset of activity and consistent response across the female study population. These results were reported at the six-month interim measurement point, and the study was designed to evaluate outcomes over a total twelve-month treatment period. The company did not disclose full twelve-month data in this announcement.

Patient-Reported Outcomes on the AAIRS Scale

In addition to objective hair count measurements, Study '207' incorporated patient-reported outcomes using the Androgenetic Alopecia Impact Rating Scale, referred to in the disclosure as the AAIRS. This instrument was used to capture participants' own perceptions of changes in their hair coverage over the course of treatment. The company reported that 88.9% of participants in the once daily dosing arm rated their hair coverage as 'improved' or 'much improved' at Month 6, while 90.0% of participants in the twice daily arm reported the same level of improvement on the AAIRS.

The high proportion of participants reporting subjective benefit across both dosing arms was highlighted by Veradermics as supporting the clinical meaningfulness of the objective hair count data. The company noted that this alignment between objective measurement and patient-reported perception is a relevant factor in assessing the overall clinical profile of an investigational hair loss therapy. Patient-reported outcomes are increasingly recognized by regulatory agencies as important components of clinical evidence packages for dermatology indications.

Investigator Assessments of Hair Coverage Improvement

Beyond patient-reported outcomes, Study '207' also incorporated independent assessments by clinical investigators, who evaluated hair coverage improvement using the same 'improved' or 'much improved' grading system applied on the AAIRS scale. According to the company's disclosure, investigators graded 100% of female participants in the once daily dosing arm and 90% of participants in the twice daily dosing arm as having 'improved' or 'much improved' hair coverage at Month 6.

The convergence of patient-reported and investigator-assessed outcomes across both dosing arms reinforces the internal consistency of the trial results as reported by Veradermics. The company presented these independent assessments as further evidence supporting the clinical meaningfulness of the hair count data. Notably, the investigator grading of 100% improvement in the once daily arm represents a particularly high level of concordance between the treating clinicians and the objective hair count measurements recorded in the same group of participants.

Early Onset of Hair Growth Observed at Month 2

One of the findings highlighted by Veradermics in its July 15, 2026 announcement was the observation of hair growth onset as early as Month 2, which the company described as the earliest measured time point in Study '207.' At that two-month assessment, 67.2% of female participants were graded by investigators as demonstrating improvement in hair coverage, and 63.2% of participants self-reported improvement in hair coverage at the same time point.

The company characterized this early-onset response as a component of VDPHL01's potentially differentiated clinical profile. Early visible response to treatment is considered clinically relevant in the pattern hair loss setting, as patients and clinicians frequently cite treatment latency as a limiting factor with existing therapies. The disclosure does not provide a direct comparative analysis against other approved or investigational hair loss treatments, and the company's characterization of differentiation reflects its own assessment of the data rather than a head-to-head clinical comparison.

Safety Profile and Tolerability in Female Participants

The company reported that VDPHL01 was generally well tolerated among female participants in Study '207' during the six-month evaluation period. The filing states that there were no treatment-related serious adverse events and no adverse events of special interest of cardiac origin reported in the female cohort. This safety profile is particularly relevant given that systemic minoxidil formulations have historically been associated with cardiovascular-related side effects, which has influenced dosing strategies across the class.

The most common adverse events reported among female participants were hypertrichosis, meaning unwanted hair growth in areas other than the scalp, and peripheral edema, which refers to swelling typically affecting the extremities. Both of these adverse events are consistent with the known pharmacological profile of minoxidil-based therapies. The absence of cardiac-origin adverse events of special interest and serious treatment-related adverse events at the six-month mark represents an encouraging safety signal for an extended-release oral formulation at the doses studied, though the company's disclosure appropriately notes that these are early-phase results subject to the limitations of an open-label study design.

Press Release and Investor Presentation Accompanying the Announcement

Alongside the current disclosure filed on July 15, 2026, Veradermics furnished two exhibits: Exhibit 99.1, consisting of the press release issued by the company on the same date, and Exhibit 99.2, consisting of the investor presentation presented by the company on its associated conference call and webcast. Both exhibits are incorporated by reference into the current disclosure and were made available to the public in connection with the topline data announcement.

The company specified that the information furnished under the Regulation FD Disclosure item and the associated exhibits are not deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, and are therefore not subject to the liabilities of that section. This distinction is standard practice for Regulation FD disclosures and does not affect the availability or accessibility of the information to investors and the public. The disclosure was signed by Reid Waldman, M.D., in his capacity as Chief Executive Officer of Veradermics, Incorporated.

Key Risk Factors Disclosed by Veradermics

Veradermics included a comprehensive forward-looking statements section in its disclosure, identifying a range of material risks applicable to the company and its lead product candidate. The company explicitly acknowledged its limited operating history and the fact that it has no products currently approved for commercial sale. It further disclosed that it has incurred substantial losses since inception and expects to continue incurring substantial and increasing losses for the foreseeable future, requiring significant additional financing to advance its development programs.

Additional risks cited by the company include the possibility that adverse events or undesirable side effects could be identified in VDPHL01's ongoing or future clinical evaluation, competition from other companies active in the pattern hair loss treatment landscape, and the risk that regulatory approval for VDPHL01 may not be obtained or may be significantly delayed. The company noted that its success is expected to depend substantially on the approval and successful commercialization of VDPHL01, and that failure to achieve this would materially harm the business. These disclosures reflect the inherent uncertainties associated with clinical-stage biopharmaceutical development and are consistent with risk disclosures made in the company's Annual Report on Form 10-K for the period ended December 31, 2025.

Context of VDPHL01 in the Pattern Hair Loss Treatment Landscape

Pattern hair loss, clinically referred to as androgenetic alopecia, affects a broad population of adults and has historically been treated with a limited number of approved pharmacological options. Oral minoxidil has emerged as an area of growing clinical interest for the treatment of both male and female pattern hair loss, with research into extended-release formulations focused on optimizing the pharmacokinetic profile of the compound to potentially improve efficacy and tolerability outcomes relative to immediate-release versions.

Veradermics has positioned VDPHL01 as a proprietary extended-release formulation intended to deliver minoxidil in a manner that may offer clinical advantages. The Phase 2 data from Study '207' represent the company's most advanced publicly disclosed clinical evidence for VDPHL01 to date. The company did not disclose in this announcement specific comparisons to commercially available minoxidil products or other investigational compounds, and the forward-looking statements section of the disclosure cautions that the interpretation and significance of clinical data from Study '207' and other trials are subject to risks and uncertainties. VDPHL01 has not yet completed Phase 3 clinical evaluation or received regulatory approval from the U.S. Food and Drug Administration or any other regulatory authority.